Clinical Trial Update: Evaluation of Efficacy and Safety of Brazikumab (MEDI2070) in Participants With Active, Moderate to Severe Crohn's Disease [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating brazikumab (MEDI2070) for active moderate-to-severe Crohn's disease was terminated with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Brazikumab

Snippet

Sponsor: AstraZeneca | Conditions: Crohn's Disease | Phase 2 | Status: TERMINATED | Results posted: 2020-05-15